Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for MJardin Group's EV-to-EBIT or its related term are showing as below:
MJARF's EV-to-EBIT is not ranked *
in the Drug Manufacturers industry.
Industry Median: 15.77 * Ranked among companies with meaningful EV-to-EBIT only.
MJardin Group (OTCPK:MJARF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
MJardin Group's Enterprise Value for the quarter that ended in Sep. 2021 was $140.85 Mil.
MJardin Group's EBIT for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MJardin Group EV-to-EBIT Related Terms
MJardin Group EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for MJardin Group's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, MJardin Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MJardin Group EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MJardin Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where MJardin Group's EV-to-EBIT falls into.
MJardin Group's current Enterprise Value is $0.00 Mil.
MJardin Group's EBIT for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MJardin Group (MJARF) has a EV-to-EBIT of 0.00 as of Jul. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on MJardin Group and its competitors.
Is MJardin Group's EV-to-EBIT too high?
MJardin Group's current EV-to-EBIT is 0.00.
How does MJardin Group's EV-to-EBIT compare to EAPH and FPSUF?
MJardin Group's EV-to-EBIT of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-EBIT is 15.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.77, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on MJardin Group and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MJardin Group's current EV-to-EBIT is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MJardin Group stock overvalued right now?
MJardin Group (MJARF) has a current EV-to-EBIT of 0.00. The current EV-to-EBIT is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For MJardin Group (MJARF), the current EV-to-EBIT is 0.00 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MJardin Group Inc is a Canada based cannabis cultivation and management company. It is engaged in the cultivation, processing, and distribution of medical cannabis. The company's operating segment includes Cultivation management in USA and Cultivation operations in Canada. It generates maximum revenue from the Cultivation management in USA segment. Cultivation management in USA segment engaged in the management services to owners of cultivation and dispensary facilities. The services provided are consulting, design, operational, and other management services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MJARF has been successfully added to your 
